Scientific Committee meeting

Scientific Committee meeting drives forward exciting plans for DISCOVER publications in 2018

 

DISCOVER Scientific Committee members met in London, UK, on 27–28 November to discuss the progress of the study and to plan for future publications

 

DISCOVER featured during special session at IDF 2017

DISCOVER featured during special session at IDF 2017

 

DISCOVER baseline data presented in a series of talks during the session entitled ‘Latest diabetes clinical trials’ at the IDF congress in Abu Dhabi

 

Extent of therapeutic inertia across the world – a systematic review

Extent of therapeutic inertia across the world – a systematic review

 

Systematic review of therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes published in Diabetes, Obesity and Metabolism.

 

The DISCOVER study

 

DISCOVER is a global, prospective, observational study of patients with type 2 diabetes who are starting second-line glucose-lowering therapy. The study has enrolled over 15 000 patients in 38 countries across six continents, and will provide a comprehensive and contemporary picture of treatment patterns and outcomes in patients with type 2 diabetes worldwide.

 

Type 2 diabetes and real world evidence

 

The DISCOVER study is designed to generate real world evidence (RWE) about people living with type 2 diabetes across the globe. RWE is key to understanding more about type 2 diabetes and how it is managed in day-to-day clinical practice, and therefore contributes to improved disease management.

 

DISCOVER publications

 

The DISCOVER study will provide unprecedented global insights into the treatment of type 2 diabetes. The DISCOVER Scientific Committee is planning a series of abstracts, posters, presentations and journal articles about the DISCOVER study design and results at global, regional and local levels.

 

The DISCOVER study

The DISCOVER study

 

DISCOVER is a global, prospective, observational study of patients with type 2 diabetes who are starting second-line glucose-lowering therapy. The study has enrolled over 15 000 patients in 38 countries across six continents, and will provide a comprehensive and contemporary picture of treatment patterns and outcomes in patients with type 2 diabetes worldwide.

 
 

Type2 diabetes and real world evidence

Type 2 diabetes and real world evidence

The DISCOVER study is designed to generate real world evidence (RWE) about people living with type 2 diabetes across the globe. RWE is key to understanding more about type 2 diabetes and how it is managed in day-to-day clinical practice, and therefore contributes to improved disease management.

 

DISCOVER publications

DISCOVER publications

 

The DISCOVER study will provide unprecedented global insights into the treatment of type 2 diabetes. The DISCOVER Scientific Committee is planning a series of abstracts, posters, presentations and journal articles about the DISCOVER study design and results at global, regional and local levels.